Pharmacological management of breathlessness in advanced disease

Progress in Palliative Care

Volumn 16, Issue 1, 2008, Pages 15-20

  Abernethy, Amy P ^a,b   Uronis, Hope E ^a   Wheeler, Jane L ^a   Currow, David C ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

Analgesics; Chronic obstructive pulmonary disease; Dyspnoea; Neoplasms; Opioid; Oxygen; Palliative care; Terminal care

Indexed keywords

ALPRAZOLAM; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CLONAZEPAM; DIAZEPAM; FUROSEMIDE; HELIOX; HELIOX 28; MIDAZOLAM; MORPHINE; MORPHINE SULFATE; NARCOTIC ANALGESIC AGENT; OXYGEN; PHENOTHIAZINE DERIVATIVE; PLACEBO; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANOREXIA; ANXIETY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SAFETY; DYSPNEA; EXERCISE TOLERANCE; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; HUMAN; MONOTHERAPY; OXYGEN THERAPY; PALLIATIVE THERAPY; QUALITY OF LIFE; RATING SCALE; REVIEW; SEDATION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 49749131220     PISSN: 09699260     EISSN: None     Source Type: Journal    
DOI: 10.1179/096992608X291243     Document Type: Review

References (46)

1. American Thoracic Society Dyspnea. Mechanisms, assessment, and management: A consensus statement. Am J Respir Crit Care Med 1999; 159: 321-340.
2. Harver A, Mahler DA, Schwartzstein RM et al. Descriptors of breathlessness in healthy individuals: Distinct and separable constructs. Chen 2000; 118: 679-690.
3. Tanaka K, Akechi T, Okuyama T et al. Development and validation of the Cancer Dyspnoea Scale: A multidimensional, brief, self-rating scale. Br J Cancer 2000; 82: 800-805.
4. Burdon JG, Pain MC, Rubinfeld AR et al. Chronic lung diseases and the perception of breathlessness: A clinical perspective. Eur Respir J 1994; 7: 1342-1349.
5. Pauwels RA, Buist AS, Calverley PM et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
6. Currow D, Abernethy A, Frith P. Morphine for management of refractory dyspnoea. BMJ 2003; 327: 1288-1289.
7. Leach RM. Palliative medicine and onn-malignant, end-stage respiratory disease. In: Doyle D. Hanks G. Cherny N et al (eds) Oxford Texthook of Palliative Medicine, 3rd edn. New York: Oxford University Press, 2005.
8. Eckenhoff JE, Oech SR. The effects of narcotics and antagonists upon respiration and circulation in man. A review. Clin Pharmacol Ther 1960; 1: 483-524.
9. Weil JV, McCullough RE, Kline JS et al. Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man. N Engl J Med 1975; 292: 1103-1106.
10. Santiago TV. Pugliese AC, Edelman NH. Control of breathing during methadone addiction. Am J Med 1977; 62: 347-354.
11. Kryger MH, Yacoub O, Dosman J et al. Effect of meperidine on occlusion pressure responses to hypercapnia and hypoxia with and Without external inspiratory resistance. Am Rev Respir Dis 1976; 114: 333-340.
12. Santiago TV, Johnson J, Riley DJ et al. Effects of morphine on ventilatory response to exercise. J Appl Physiol 1979; 47: 112-118.
13. Jennings AL, Davies AN, Higgins JP et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57: 939-944.
14. Abernethy AP, Currow DC, Frith P et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003; 327: 523-528.
15. Navigante AH. Cerchietti LCA, Castro MA et al. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnoea perception in patients with advanced cancer. J Pain Symptom Manage 2006; 31: 38-47.
16. Kim HF, Kunik ME, Molinari VA et al. Functional impairment in COPD patients: The impact of anxiety and depression. Psychosomatics 2000; 41: 465-471.
17. Mitchell-Heggs P, Murphy K, Minty K et al. Diazepam in the treatment of dyspnoea in the 'Pink Puffer' syndrome. Q J Med 1980; 49: 9-20.
18. Woodcock AA, Gross ER, Geddes DM. Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. BMJ 1981; 283: 343-346.
19. Sen D, Jones G, Leggat PO. The response of the breathless patient treated with diazepam. Br J Clin Pract 1983; 37: 232-233.
20. Man GC, Hsu K, Sproule BJ. Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest 1986; 90: 832-836.
21. Greene JG, Pucino E, Carlson JD et al. Effects of alprazolam on respiratory drive, anxiety, and dyspnea in chronic airflow obstruction: a case study. Pharmacothery 1989: 9: 34-38.
22. Garner SJ, Eldridge FL, Wagner PG et al. Buspirone. an anxiolytic drug that stimulates respiration. Am Rev Respir Dis 1989; 139: 946-950.
23. Mendelson WB, Martin JV, Rapoport DM. Effects of buspirone on respiration. Am Rev Respir Dis 1990; 141: 1527-1530.
24. Argyropoulou P, Patakas D, Koukou A et al. Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration 1993; 60: 216-220.
25. Singh NP, Despars JA, Stansbury DW et al. Effect of buspirone on anxiety levels and exercise tolerance in patients with chronic airflow obstruction and mild anxiety. Chest 1993; 103: 800-804
26. Papp LA, Weiss JR, Greenberg HE et al. Sertraline for chronic obstructive pulmonary disease and comorbid anxiety and mood disorders. Am J Psychiatry 1995; 152: 1531.
27. Smoller JV, Pollack MH, Systrom D et al. Sertraline effects on dyspnea in patients with obstructive airways disease. Psychosomatics 1998; 39: 24-29.
28. Burns BH, Howell JB. Disproportionately severe breathlessness in chronic bronchitis. Q J Med 1969; 38: 277-294.
29. Mueller RA, Lundberg DB, Breese GR et al. The neuropharmacology of respiratory control. Pharmacol Rev 1982; 34: 255-285.
30. Ventresca PG, Nichol GM, Barnes PJ et al. Inhaled frusemide inhibits cough induced by low chloride content solutions but not by capsaicin. Am Rev Respir Dis 1990; 142: 143-146.
31. Bianco S, Vaghi A, Robuschi M et al. Prevention of exercise-induced bionchoconstriction by inhaled frusemide. Lancet 1998; 2 252-255.
32. Bianco S, Pieroni MG, Refini RM et al. Protective effect of inhaled frusemide on allergen-induced early and late asthmatic reactions. N Engl J Med 1989; 321: 1069-1073.
33. Robuschi M, Gambaro G, Spagnotto S et al. Inhaled frusemide is highly effective in preventing ultrasonically nebulised water bronchoconstriction. Pulm Pharmacol 1989; 1: 187-191.
34. Chung KF, Barnes PJ. Loop diuretics and asthma. Pulm Pharmacol 1992; 5: 1-7.
35. Nishino T, Ide T, Sudo T et al. Inhaled frusemide greatly alleviates the sensation of experimentally induced dyspnea. Am J Respir Crit Care Med 2000; 161: 1963-1967.
36. Ong KC, Kor AC, Chong WE et al. Effects of inhaled frusemide on exertional dyspnea in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 1028-1033.
37. Nishiho T, Ide T, Sudo T et al. Inhaled frusemide greatly alleviates the sensation of experimentally induced dyspnea. Am J Respir Crit Care Med 2000; 161: 1963-1967.
38. Ahmedzai SH, Laude E, Robertson A et al. A double-blind, randomised, controlled Phase II trial of Heliox 28 gas mixture in lung cancer patients with dyspnoea on exertion. Br J Cancer 2004; 90: 366-371.
39. Booth S, Wade R, Johnson M et al. The use of oxygen in the palliation of breathlessness. A report of the expert working group of the Scientific Committee of the Association of Palliative Medicine. Respir Med 2004; 98: 66-77.
40. Bruera E, Schoeller T, MacEachern T. Symptomatic benefit of supplemental oxygen in hypoxemic patients with terminal cancer: The use of the N of 1 randomized controlled trial. J Pain Symptom Manage 1992; 7: 365-368.
41. Guyatt GH, McKim DA, Austin P et al. Appropriateness of domiciliary oxygen delivery. Chest 2000; 118: 1303-1308
42. Abernethy AP, Currow DC, Frith P et al. Prescribing palliative oxygen: A clinician survey of expected benefit and patterns of use. Palliat Med 2005; 19: 168-170.
43. Stringer E, McParland C, Hernandez P. Physician practices for prescribing supplemental oxygen in the palliative care setting. J Palliat Care 2004; 20: 303-307.
44. 2 > 55. ISRCTN 67448752, .
45. Currow DC, Fazekas B, Abernethy AP, Oxygen use - patients define symptomatic benefit discerningly. J Pain Symptom Manage 2007; 34: 113-114.
46. Booth S, Adams L. The shuttle walking test: A reproducible method for evaluating the impact of shortness of breath on functional capacity in patients with advanced cancer. Thorax 2001; 56: 146-150